

Craig P Nolan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8872898/publications.pdf>

Version: 2024-02-01

23
papers

1,961
citations

471509

17
h-index

677142

22
g-index

23
all docs

23
docs citations

23
times ranked

3399
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 1018-1029. | 9.4 | 302 |
| 2 | R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. <i>Blood</i> , 2015, 125, 1403-1410. | 1.4 | 267 |
| 3 | Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. <i>Neuro-Oncology</i> , 2015, 17, 116-121. | 1.2 | 207 |
| 4 | Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. <i>Neuro-Oncology</i> , 2016, 18, 283-290. | 1.2 | 161 |
| 5 | Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3861-3867. | 1.6 | 159 |
| 6 | Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547. | 7.0 | 107 |
| 7 | Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2010, 100, 443-447. | 2.9 | 100 |
| 8 | Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. <i>Clinical Cancer Research</i> , 2016, 22, 4786-4796. | 7.0 | 95 |
| 9 | Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 5023-5031. | 7.0 | 89 |
| 10 | Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. <i>Journal of Neuro-Oncology</i> , 2005, 75, 71-83. | 2.9 | 83 |
| 11 | Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2013, 15, 242-250. | 1.2 | 83 |
| 12 | Salvage temozolomide for prior temozolomide responders. <i>Cancer</i> , 2005, 104, 2473-2476. | 4.1 | 79 |
| 13 | Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 403-407. | 2.9 | 55 |
| 14 | A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. <i>Journal of Neuro-Oncology</i> , 2008, 87, 85-90. | 2.9 | 40 |
| 15 | Myelopathies in Patients With Cancer. <i>Archives of Neurology</i> , 2010, 67, 298-304. | 4.5 | 35 |
| 16 | Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 429-436. | 3.7 | 29 |
| 17 | Overview of metastatic disease of the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 3-23. | 1.8 | 28 |
| 18 | Leptomeningeal Metastases from Leukemias and Lymphomas. , 2005, 125, 53-69. | | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | The confused oncologic patient: a rational clinical approach. <i>Current Opinion in Neurology</i> , 2016, 29, 789-796. | 3.6 | 12 |
| 20 | Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage. <i>Neuro-Oncology Practice</i> , 2017, 4, 24-28. | 1.6 | 4 |
| 21 | Intramedullary spinal cord and leptomeningeal metastases from intracranial low-grade oligodendroglioma. <i>Clinical Imaging</i> , 2014, 38, 505-507. | 1.5 | 3 |
| 22 | Lymphomatous Meningitis. <i>American Journal of Cancer</i> , 2002, 1, 423-434. | 0.4 | 1 |
| 23 | Pearls: Primary Brain Tumors. <i>Seminars in Neurology</i> , 2010, 30, 005-009. | 1.4 | 1 |